التفاصيل البيبلوغرافية
| العنوان: |
Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double‐blind, placebo‐controlled, multicenter, phase II trial |
| المؤلفون: |
Choi, C. H., Kwon, J. G., Kim, S. K., Myung, S.‐J., Park, K. S., Sohn, C.‐I., Rhee, P.‐L., Lee, K. J., Lee, O. Y., Jung, H.‐K., Jee, S. R., Jeen, Y. T., Choi, M.‐G., Choi, S. C., Huh, K. C., Park, H. |
| المصدر: |
Neurogastroenterology & Motility ; volume 27, issue 5, page 705-716 ; ISSN 1350-1925 1365-2982 |
| بيانات النشر: |
Wiley |
| سنة النشر: |
2015 |
| المجموعة: |
Wiley Online Library (Open Access Articles via Crossref) |
| الوصف: |
Background Probiotics can be beneficial in irritable bowel syndrome ( IBS ). Mosapride citrate, a selective 5‐ HT 4 receptor agonist, stimulates gastrointestinal motility. We investigated the efficacy of combination therapy with probiotics and mosapride for non‐diarrheal‐type IBS . Methods Two hundred and eighty‐five IBS patients were randomly assigned to either a combination of probiotics ( Bacillus subtilis and Streptococcus faecium ) and mosapride at one of four different doses or a placebo for 4 weeks. The primary outcome was the proportion of patients experiencing adequate relief ( AR ) of global IBS symptoms at week 4. The secondary outcomes included subject's global assessment ( SGA ) of IBS symptom relief, individual symptoms, stool parameters, and IBS ‐quality of life. Key Results The proportion of AR at week 4 was significantly higher in all treatment groups compared to the placebo group (53.7% in group 1, 55.0% in group 2, 55.2% in group 3, 53.6% in group 4 [the highest dose], and 35.1% in placebo group, respectively, p < 0.05). The proportion of patients reporting ‘completely or considerably relieved’ in the SGA was higher in the treatment groups than in the placebo group. The abdominal pain/discomfort score in the treatment group 4 was more prominently improved compared with that of the placebo group. In patients with constipation‐predominant IBS , the improvements in stool frequency and consistency were significantly higher in the treatment groups 4 and 1, respectively, than those in the placebo group. Conclusions & Inferences Combination therapy with probiotics and mosapride is effective for relief of symptoms in patients with non‐diarrheal‐type IBS . The study has been registered in the US National Library of Medicine ( http://www.clinicaltrials.govTest , NCT01505777). |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1111/nmo.12544 |
| الإتاحة: |
https://doi.org/10.1111/nmo.12544Test |
| حقوق: |
http://onlinelibrary.wiley.com/termsAndConditions#vorTest |
| رقم الانضمام: |
edsbas.5DDC685D |
| قاعدة البيانات: |
BASE |
